Cardiovascular Biologics Market Expected to Reach USD 4.23 Billion by 2033 Amid Advances in RNA and Biologic Therapies | DataM Intelligence
Comunicato Precedente
Comunicato Successivo
Growth Drivers: Innovation Meets Unmet Clinical Need
Download PDF Brochure: https://www.datamintelligence.com/download-sample/cardiovascular-biologics-market
Browse in-depth TOC on "Cardiovascular Biologics Market"
70 – Tables
66 – Figures
195 – Pages
Market Segmentation Analysis
By Biologic Type
The market is categorized into Monoclonal Antibodies (mAbs), siRNA-Based Therapeutics, Recombinant Proteins, and Others.
By Indication
By Distribution Channel
Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/cardiovascular-biologics-market
Regional Insights
United States
The U.S. market held 45% global share (USD 990 million in 2024) and is projected to reach USD 1.95 billion by 2033, expanding at 7.8% CAGR.
Japan
Japan's market reached USD 210 million in 2024 and is expected to grow to USD 420 million by 2033, registering a 7.9% CAGR.
Competitive Landscape
Key players in this market include Regeneron Pharmaceuticals, Inc.; Amgen Inc.; Novartis Pharmaceuticals Corporation; Alnylam Pharmaceuticals, Inc.; Genentech USA, Inc.; Reliance Life Sciences; Biocon Biologics Limited; and Shanghai Junshi Biosciences Co.
Highlights (FY2024):
Market Outlook and Strategic Implications
The forecast to USD 4.23 billion by 2033 at a 7.5% CAGR suggests a steady but relatively moderate growth path compared to some other biologics segments. Key strategic implications include:
Recent Industry Developments
Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=cardiovascular-biologics-market
Conclusion
The cardiovascular biologics market is entering a phase of sustained growth, anchored by biologic innovations targeting cardiovascular disease pathways. With the market expected to increase from USD 2.20 billion in 2024 to USD 4.23 billion by 2033, the 7.5% CAGR underlines the long-term potential of biologics in cardiovascular care. According to DataM Intelligence, companies that invest in next‐generation biologic platforms (such as siRNA, gene therapies, recombinant proteins) and expand indications beyond traditional lipid-lowering will be best positioned to capture growth.
Related Report:
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cardiovascular-biologics-market-expected-to-reach-usd-4-23-billion-by-2033-amid-advances-in-rna-and-biologic-therapies--datam-intelligence-302615679.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
